Boston Scientific Gross Profit 2012-2026 | BSX
Boston Scientific annual/quarterly gross profit history and growth rate from 2012 to 2026. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
- Boston Scientific gross profit for the quarter ending March 31, 2026 was $3.613B, a 12.55% increase year-over-year.
- Boston Scientific gross profit for the twelve months ending March 31, 2026 was $14.257B, a 18.29% increase year-over-year.
- Boston Scientific annual gross profit for 2025 was $13.853B, a 20.57% increase from 2024.
- Boston Scientific annual gross profit for 2024 was $11.49B, a 16.12% increase from 2023.
- Boston Scientific annual gross profit for 2023 was $9.895B, a 13.4% increase from 2022.
|
Boston Scientific Annual Gross Profit (Millions of US $) |
|
|---|---|
| 2025 | $13,853 |
| 2024 | $11,490 |
| 2023 | $9,895 |
| 2022 | $8,726 |
| 2021 | $8,177 |
| 2020 | $6,448 |
| 2019 | $7,619 |
| 2018 | $7,010 |
| 2017 | $6,455 |
| 2016 | $5,962 |
| 2015 | $5,304 |
| 2014 | $5,170 |
| 2013 | $4,969 |
| 2012 | $4,900 |
| 2011 | $4,963 |
|
Boston Scientific Quarterly Gross Profit (Millions of US $) |
|
|---|---|
| 2026-03-31 | $3,613 |
| 2025-12-31 | $3,678 |
| 2025-09-30 | $3,542 |
| 2025-06-30 | $3,424 |
| 2025-03-31 | $3,210 |
| 2024-12-31 | $3,096 |
| 2024-09-30 | $2,897 |
| 2024-06-30 | $2,850 |
| 2024-03-31 | $2,647 |
| 2023-12-31 | $2,579 |
| 2023-09-30 | $2,426 |
| 2023-06-30 | $2,541 |
| 2023-03-31 | $2,349 |
| 2022-12-31 | $2,231 |
| 2022-09-30 | $2,191 |
| 2022-06-30 | $2,233 |
| 2022-03-31 | $2,071 |
| 2021-12-31 | $2,155 |
| 2021-09-30 | $2,032 |
| 2021-06-30 | $2,132 |
| 2021-03-31 | $1,858 |
| 2020-12-31 | $1,709 |
| 2020-09-30 | $1,790 |
| 2020-06-30 | $1,212 |
| 2020-03-31 | $1,737 |
| 2019-12-31 | $2,053 |
| 2019-09-30 | $1,930 |
| 2019-06-30 | $1,873 |
| 2019-03-31 | $1,763 |
| 2018-12-31 | $1,831 |
| 2018-09-30 | $1,721 |
| 2018-06-30 | $1,751 |
| 2018-03-31 | $1,707 |
| 2017-12-31 | $1,735 |
| 2017-09-30 | $1,585 |
| 2017-06-30 | $1,625 |
| 2017-03-31 | $1,510 |
| 2016-12-31 | $1,573 |
| 2016-09-30 | $1,511 |
| 2016-06-30 | $1,487 |
| 2016-03-31 | $1,391 |
| 2015-12-31 | $1,404 |
| 2015-09-30 | $1,349 |
| 2015-06-30 | $1,303 |
| 2015-03-31 | $1,248 |
| 2014-12-31 | $1,327 |
| 2014-09-30 | $1,296 |
| 2014-06-30 | $1,310 |
| 2014-03-31 | $1,237 |
| 2013-12-31 | $1,282 |
| 2013-09-30 | $1,225 |
| 2013-06-30 | $1,279 |
| 2013-03-31 | $1,183 |
| 2012-12-31 | $1,238 |
| 2012-09-30 | $1,177 |
| 2012-06-30 | $1,250 |
| 2012-03-31 | $1,235 |
| 2011-12-31 | $1,188 |
| 2011-09-30 | $1,194 |
| 2011-06-30 | $1,287 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $91.831B | $20.074B |
| Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $174.688B | 19.48 |
| Stryker (SYK) | United States | $129.889B | 24.88 |
| Medtronic (MDT) | Ireland | $111.968B | 15.57 |
| EssilorLuxottica (ESLOY) | France | $107.724B | 0.00 |
| Medline (MDLN) | United States | $59.904B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $45.712B | 0.00 |
| GE HealthCare Technologies (GEHC) | United States | $33.391B | 15.98 |
| ResMed (RMD) | United States | $33.341B | 22.26 |
| Agilent Technologies (A) | United States | $32.516B | 20.44 |
| Koninklijke Philips (PHG) | Netherlands | $27.260B | 16.18 |
| Terumo (TRUMY) | Japan | $19.854B | 23.21 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.025B | 11.36 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $14.227B | 0.00 |
| Insulet (PODD) | United States | $13.640B | 39.54 |
| Baxter (BAX) | United States | $8.854B | 7.56 |
| Sunny Optical Technology (SNPTF) | China | $8.381B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.537B | 28.15 |
| Demant (WILYY) | Denmark | $6.395B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $5.247B | 15.90 |
| Envista Holdings (NVST) | United States | $4.301B | 21.99 |
| BillionToOne (BLLN) | United States | $3.729B | 0.00 |
| DiaSorin S.p.A (DSRLF) | Italy | $3.666B | 0.00 |
| ICU Medical (ICUI) | United States | $3.141B | 20.47 |
| Prestige Consumer Healthcare (PBH) | United States | $2.676B | 12.62 |
| Haemonetics (HAE) | United States | $2.664B | 11.65 |
| LeMaitre Vascular (LMAT) | United States | $2.611B | 48.16 |
| Phibro Animal Health (PAHC) | United States | $2.347B | 20.67 |
| GN Store Nord (GNNDY) | Denmark | $2.270B | 21.90 |
| Neogen (NEOG) | United States | $2.050B | 44.86 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $2.028B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $1.794B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.654B | 32.89 |
| Curaleaf Holdings (CURLF) | Canada | $1.584B | 0.00 |
| Perrigo (PRGO) | Ireland | $1.495B | 3.96 |
| AtriCure (ATRC) | United States | $1.429B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.386B | 15.91 |
| Kestra Medical Technologies (KMTS) | United States | $1.043B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.953B | 164.50 |
| QuidelOrtho (QDEL) | United States | $0.943B | 6.53 |
| Lumexa Imaging Holdings (LMRI) | United States | $0.896B | 0.00 |
| InMode (INMD) | Israel | $0.857B | 9.40 |
| Omeros (OMER) | United States | $0.827B | 6.49 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.789B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.766B | 0.00 |
| CeriBell (CBLL) | United States | $0.683B | 0.00 |
| Brainsway (BWAY) | Israel | $0.546B | 55.68 |
| Valneva SE (VALN) | France | $0.532B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.468B | 11.18 |
| Cresco Labs (CRLBF) | United States | $0.458B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.424B | 0.00 |
| Verano Holdings (VRNO) | United States | $0.415B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.367B | 25.70 |
| SNDL (SNDL) | Canada | $0.366B | 0.00 |
| Cerus (CERS) | United States | $0.363B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.311B | 126.00 |
| Evolus (EOLS) | United States | $0.278B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.259B | 0.00 |
| MacroGenics (MGNX) | United States | $0.229B | 0.00 |
| Owens & Minor (OMI) | United States | $0.217B | 2.17 |
| Accendra Health (ACH) | United States | $0.215B | 2.96 |
| Utah Medical Products (UTMD) | United States | $0.210B | 18.94 |
| High Tide (HITI) | Canada | $0.205B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.205B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.194B | 57.17 |
| TerrAscend (TSNDF) | Canada | $0.193B | 0.00 |
| Organigram Global (OGI) | Canada | $0.191B | 0.00 |
| Apyx Medical (APYX) | United States | $0.166B | 0.00 |
| Quanterix (QTRX) | United States | $0.158B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.157B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.152B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.145B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.143B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.133B | 0.00 |
| Fonar (FONR) | United States | $0.115B | 16.53 |
| Jushi Holdings (JUSHF) | United States | $0.101B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.090B | 11.73 |
| Exagen (XGN) | United States | $0.073B | 0.00 |
| Sharps Technology (STSS) | United States | $0.065B | 0.00 |
| ImmuCell (ICCC) | United States | $0.064B | 0.00 |
| Biote (BTMD) | United States | $0.063B | 3.46 |
| INLIF (INLF) | China | $0.053B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.038B | 0.00 |
| Veru (VERU) | United States | $0.038B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.036B | 0.00 |
| Nephros (NEPH) | United States | $0.032B | 26.91 |
| United-Guardian (UG) | United States | $0.030B | 14.23 |
| Bonk (BNKK) | United States | $0.021B | 0.00 |
| Jin Medical (ZJYL) | China | $0.018B | 0.00 |
| Modular Medical (MODD) | United States | $0.013B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.012B | 0.00 |
| Flora Growth (FLGC) | United States | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| Zynex (ZYXI) | United States | $0.004B | 0.00 |
| Functional Brands (MEHA) | United States | $0.003B | 0.00 |
| Agape ATP (ATPC) | $0.003B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.002B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.002B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.001B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |